Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

SONN

Sonnet BioTherapeutics (SONN)

Sonnet BioTherapeutics Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SONN
DateTimeSourceHeadlineSymbolCompany
25/09/202422:30GlobeNewswire Inc.Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock SplitNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
18/09/202422:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
18/09/202422:30GlobeNewswire Inc.Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid TumorsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
13/09/202407:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
10/09/202406:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
04/09/202423:15GlobeNewswire Inc.Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell SeriesNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
30/08/202422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
20/08/202407:28Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
20/08/202407:27Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
19/08/202422:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
19/08/202422:45GlobeNewswire Inc.Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic CancerNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
14/08/202422:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
14/08/202422:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
14/08/202422:35GlobeNewswire Inc.Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
10/08/202407:28Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
10/08/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
24/07/202422:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
24/07/202422:30GlobeNewswire Inc.Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 StudyNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
16/07/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
16/07/202407:05Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
20/06/202422:30GlobeNewswire Inc.Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross ProceedsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
13/06/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
13/06/202422:00GlobeNewswire Inc.Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 DomainNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
28/05/202422:00GlobeNewswire Inc.Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual MeetingNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
22/05/202421:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
20/05/202423:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
17/05/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
17/05/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
17/05/202406:16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
16/05/202406:06Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:SONN